Don’t miss the latest developments in business and finance.

Lupin enters into patent license agreement with Takeda

Image
Last Updated : Sep 18 2024 | 2:04 PM IST

To commercialize Vonoprazan Tablets in India

Lupin announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company (Takeda), to commercialize Vonoprazan Tablets in the Indian market. The drug will be marketed under the brand name Lupin's Lupivon and will be available in two strengths - 10 mg and 20 mg.

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.

Powered by Capital Market - Live News

Also Read

First Published: Sep 18 2024 | 1:43 PM IST

Next Story